Should I buy or sell AlloVir stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares. View ALVR analyst ratings or view top-rated stocks .

What is AlloVir's stock price target for 2024?

3 analysts have issued 1 year price targets for AlloVir's stock. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 810.2% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts .

How have ALVR shares performed in 2023?

AlloVir's stock was trading at $5.13 on January 1st, 2023. Since then, ALVR shares have decreased by 59.8% and is now trading at $2.06. View the best growth stocks for 2023 here .

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our ALVR earnings forecast .

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) announced its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.03.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD) , Cloudera (CLDR) , Infinera (INFN) , Sonos (SONO) , Trevena (TRVN) , Abbott Laboratories (ABT) , Boeing (BA) , Delta Air Lines (DAL) , Datadog (DDOG) and FuelCell Energy (FCEL) .

When did AlloVir IPO?

(ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.49%), Massachusetts Financial Services Co. MA (0.73%), Wellington Management Group LLP (0.52%), Northern Trust Corp (0.42%), Charles Schwab Investment Management Inc. (0.36%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Agustin Melian , Ann M Leen , Beek Jeroen B Van, Beek Jeroen B Van , Brett R Hagen , David Hallal , Diana Brainard, Edward Miller, Ercem Atillasoy , Gilead Sciences, Inc, Jeffrey S Bornstein , John Robert Wilson , Juan Vera , Morana Jovan-Embiricos and Vikas Sinha. View institutional ownership trends .

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

AlloVir Stock Price, News & Analysis (NASDAQ:ALVR)

$2.06

+0.09 (+4.57%)

(As of 10:33 AM ET)

Compare

Today's Range: $1.97
▼
$2.12
50-Day Range: $1.34
▼
$2.35
52-Week Range: $1.31
▼
$7.72

Volume: 255,821 shs
Average Volume: 585,547 shs
Market Capitalization: $234.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.75

AlloVir MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 810.2% Upside
$18.75 Price Target
Short Interest: Bearish
10.17% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$37,132 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.71) to ($1.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

563rd out of 951 stocks

Biological Products, Except Diagnostic Industry

88th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
AlloVir has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.75, AlloVir has a forecasted upside of 810.2% from its current price of $2.06.
Amount of Analyst Coverage
AlloVir has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.17% of the outstanding shares of AlloVir have been sold short.
Short Interest Ratio / Days to Cover
AlloVir has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
Change versus previous month
Short interest in AlloVir has recently increased by 2.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AlloVir does not currently pay a dividend.
Dividend Growth
AlloVir does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALVR.

3.3

News and Social Media Coverage

News Sentiment
AlloVir has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for AlloVir this week, compared to 1 article on an average week.
Search Interest
5 people have searched for ALVR on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added AlloVir to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,132.00 in company stock.
Percentage Held by Insiders
39.97% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.41% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AlloVir are expected to grow in the coming year, from ($1.71) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AlloVir is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AlloVir is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AlloVir has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AlloVir Stock (NASDAQ:ALVR)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

ALVR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALVR Stock News Headlines

November 16, 2023 | finance.yahoo.com

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

November 3, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 2, 2023 | morningstar.com

AlloVir Inc Ordinary Shares ALVR

November 2, 2023 | finance.yahoo.com

AlloVir Inc (ALVR) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

AlloVir Reports Third Quarter 2023 Financial Results

September 23, 2023 | fool.com

AlloVir (NASDAQ: ALVR)

September 21, 2023 | fool.com

Why AlloVir Stock Dropped Today

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 15, 2023 | finance.yahoo.com

We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate

August 28, 2023 | finance.yahoo.com

AlloVir to Present at Upcoming Investor Conferences

August 18, 2023 | msn.com

AlloVir spikes as Bank of America starts at Buy on lead asset

August 18, 2023 | markets.businessinsider.com

AlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

August 18, 2023 | msn.com

B of A Securities Initiates Coverage of AlloVir (ALVR) with Buy Recommendation

August 18, 2023 | markets.businessinsider.com

Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)

August 8, 2023 | msn.com

Morgan Stanley Reiterates AlloVir (ALVR) Overweight Recommendation

August 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Cytokinetics (CYTK) and Guardant Health (GH)

August 3, 2023 | finance.yahoo.com

AlloVir Reports Second Quarter 2023 Financial Results

July 10, 2023 | msn.com

AlloVir: 'Takes One To Know One'

June 29, 2023 | msn.com

BlackBerry, Micron And Other Big Stocks Moving Higher In Thursday's Pre-Market Session

June 27, 2023 | finance.yahoo.com

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why

June 23, 2023 | finance.yahoo.com

Why Shares of AlloVir Plummeted This Week

June 22, 2023 | nasdaq.com

AlloVir Prices Public Offering

June 22, 2023 | benzinga.com

Why AlloVir Stock Is Diving Thursday

June 22, 2023 | investorplace.com

Why Is AlloVir (ALVR) Stock Down 23% Today?

June 22, 2023 | seekingalpha.com

AlloVir shares slide on pricing $75M of stock offering

June 22, 2023 | markets.businessinsider.com

Pre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE…

See More Headlines

Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALVR
CUSIP: N/A
CIK: 1754068
Web: www.allovir.com
Phone: 617-433-2605
Fax: N/A
Employees: 114
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.75
High Stock Price Target: $20.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +851.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-168,710,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.17%
Return on Assets: -64.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.65
Quick Ratio: 6.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.71 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 114,060,000
Free Float: 68,473,000
Market Cap: $224.70 million
Optionable: Not Optionable
Beta: 1.03

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. David L. Hallal (Age 57)
Executive Chairman of the Board
Comp: $254.38k
Dr. Diana M. Brainard M.D. (Age 52)
CEO & Director
Comp: $978.99k
Mr. Vikas Sinha C.A. (Age 60)
CPA, M.B.A., President, CFO & Director
Comp: $536.21k
Mr. Edward Miller J.D. (Age 58)
General Counsel & Secretary
Comp: $618.39k
Mr. Brett R. Hagen (Age 50)
Chief Accounting Officer
Mr. Dana M. Alexander (Age 47)
Senior Vice President of Technical Operations
Dr. Ann M. Leen Ph.D. (Age 46)
Chief Scientific Officer
Ms. Sonia Choi
Senior Vice President of Corporate Affairs & Investor Relations
Mr. Ugo Capolino Perlingieri
Head & GM of Europe and Middle East Operations
Ms. Cintia Piccina Pharm.D. (Age 50)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALVR Stock Analysis - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings or view top-rated stocks.
What is AlloVir's stock price target for 2024?: 3 analysts have issued 1 year price targets for AlloVir's stock. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 810.2% from the stock's current price.
View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts.
How have ALVR shares performed in 2023?: AlloVir's stock was trading at $5.13 on January 1st, 2023. Since then, ALVR shares have decreased by 59.8% and is now trading at $2.06.
View the best growth stocks for 2023 here.
When is AlloVir's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our ALVR earnings forecast.
How were AlloVir's earnings last quarter?: AlloVir, Inc. (NASDAQ:ALVR) announced its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.03.

What other stocks do shareholders of AlloVir own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).
When did AlloVir IPO?: (ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
Who are AlloVir's major shareholders?: AlloVir's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.49%), Massachusetts Financial Services Co. MA (0.73%), Wellington Management Group LLP (0.52%), Northern Trust Corp (0.42%), Charles Schwab Investment Management Inc. (0.36%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends.
How do I buy shares of AlloVir?: Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALVR) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial